![](/img/cover-not-exists.png)
Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib
Qin, Ya-Zhen, Jiang, Qian, Lai, Yue-Yun, Jiang, Hao, Shi, Hong-Xia, Zhao, Xiao-Su, Liu, Yan-Rong, Huang, Xiao-JunLanguage:
english
Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2016.1239260
Date:
October, 2016
File:
PDF, 1.28 MB
english, 2016